411 related articles for article (PubMed ID: 19627400)
1. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.
Xie Y; Bai O; Zhang H; Yuan J; Zong S; Chibbar R; Slattery K; Qureshi M; Wei Y; Deng Y; Xiang J
J Cell Mol Med; 2010 Nov; 14(11):2655-66. PubMed ID: 19627400
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
3. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.
Hao S; Bai O; Li F; Yuan J; Laferte S; Xiang J
Immunology; 2007 Jan; 120(1):90-102. PubMed ID: 17073943
[TBL] [Abstract][Full Text] [Related]
4. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
5. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
6. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
Liu Y; Qureshi M; Xiang J
Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
[TBL] [Abstract][Full Text] [Related]
7. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
[TBL] [Abstract][Full Text] [Related]
8. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor.
Shi M; Su L; Hao S; Guo X; Xiang J
Tumori; 2005; 91(6):531-8. PubMed ID: 16457153
[TBL] [Abstract][Full Text] [Related]
9. CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.
Zhang H; Xie Y; Li W; Chibbar R; Xiong S; Xiang J
Cell Mol Immunol; 2011 Jan; 8(1):23-30. PubMed ID: 21200381
[TBL] [Abstract][Full Text] [Related]
10. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
11. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
13. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity.
Liu Y; Zhang W; Chan T; Saxena A; Xiang J
Leuk Res; 2002 Aug; 26(8):757-63. PubMed ID: 12191571
[TBL] [Abstract][Full Text] [Related]
14. Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.
Xie Y; Zhang X; Zhao T; Li W; Xiang J
Biochem Biophys Res Commun; 2013 Aug; 438(1):152-5. PubMed ID: 23876314
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
16. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
17. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70.
Moroi Y; Mayhew M; Trcka J; Hoe MH; Takechi Y; Hartl FU; Rothman JE; Houghton AN
Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3485-90. PubMed ID: 10725409
[TBL] [Abstract][Full Text] [Related]
18. Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.
Shanker A; Buferne M; Schmitt-Verhulst AM
Immunology; 2010 Jan; 129(1):41-54. PubMed ID: 20050329
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
